Details for Patent: 8,153,632

✉ Email this page to a colleague

Which drugs does patent 8,153,632 protect, and when does it expire?

Patent 8,153,632 protects VONJO and is included in one NDA.

This patent has forty-nine patent family members in twenty-one countries.

Summary for Patent: 8,153,632

Title:	Oxygen linked pyrimidine derivatives
Abstract:	The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.
Inventor(s):	Blanchard; Stephanie (Singapore, SG), Lee; Cheng Hsia Angeline (Singapore, SG), Nagaraj; Harish Kumar Mysore (Singapore, SG), Poulsen; Anders (Singapore, SG), Sun; Eric T. (Singapore, SG), Tan; Yee Ling Evelyn (Singapore, SG), William; Anthony Deodaunia (Singapore, SG)
Assignee:	S*BIO Pte Ltd. (Singapore, SG)
Application Number:	12/093,867
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Device;

Drugs Protected by US Patent 8,153,632

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cti Biopharma Corp	VONJO	pacritinib citrate	CAPSULE;ORAL	208712-001	Feb 28, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)	⤷ Sign Up
Cti Biopharma Corp	VONJO	pacritinib citrate	CAPSULE;ORAL	208712-001	Feb 28, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		TREATMENT OF MYELOFIBROSIS WITH PACRITINIB	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,153,632

PCT Information
PCT Filed	November 15, 2006	PCT Application Number:	PCT/SG2006/000352
PCT Publication Date:	May 24, 2007	PCT Publication Number:	WO2007/058627

International Family Members for US Patent 8,153,632

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E469158	⤷ Sign Up
Australia	2006316071	⤷ Sign Up
Australia	2006316072	⤷ Sign Up
Brazil	PI0618552	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.